SCHEMBL21117650

SCHEMBL21117650

COc1ccc(CN(c2cscn2)S(=O)(=O)c2cc(C=O)c(O)cc2F)cc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACLY P53396 1/20 0.39
ERN1 O75460 2/20 0.35
TRIM24 O15164 1/20 0.35
TYR P14679 1/20 0.35
TRIM33 Q9UPN9 1/20 0.35
CNR2 P34972 4/20 0.35
CNR1 P21554 3/20 0.35
TAS2R14 Q9NYV8 4/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
MMP9 P14780 2/20 0.33
MMP1 P03956 1/20 0.33
MMP13 P45452 1/20 0.33
KEAP1 Q14145 2/20 0.33
NFE2L2 Q16236 2/20 0.33
APLNR P35414 1/20 0.33
NR3C1 P04150 1/20 0.32
PGR P06401 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19613502 0.92 ACLY (0.37) ACLYCNR2CNR1TAS2R14MEN1
SCHEMBL19631690 0.88 SCN8A (0.35) ACLYCNR2CNR1MEN1KMT2A
SCHEMBL19613710 0.82 ACLY (0.38) ACLYCNR2CNR1TAS2R14MMP9
SCHEMBL19613447 0.82 ACLY (0.44) ACLYCNR2CNR1MEN1KMT2A
SCHEMBL19631521 0.80 ACLY (0.36) ACLYCNR2CNR1MMP9MMP1
SCHEMBL22590204 0.80 SCN8A (0.41) ACLYCNR2CNR1MMP9MMP1
SCHEMBL19614293 0.79 SCN8A (0.42)
SCHEMBL19614291 0.79 SCN8A (0.42)
SCHEMBL19631623 0.79 MMP9 (0.36) ACLYCNR2CNR1MMP9MMP1
SCHEMBL21772969 0.78 CNR2 (0.42) ACLYCNR2CNR1TAS2R14MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10662184-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2020-05-26 US disclosed
US-20190194184-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2019-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10662184-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B ACLY 2816/4885ERN1 3677/4885TRIM24 4863/4885
US-20190194184-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B ACLY 2816/4885ERN1 3677/4885TRIM24 4863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.